Sanofi's Regulatory and Clinical Updates in October 2025

In October 2025, Sanofi published several press releases providing updates on regulatory reviews and clinical developments. Key highlights include: a negative opinion from the European Medicines Agency’s CHMP on Rezurock for chronic graft-vs-host disease, with Sanofi seeking re-examination; a positive CHMP recommendation for Wayrilz to treat immune thrombocytopenia; superior protection demonstrated by Sanofi’s high-dose influenza vaccine for older adults; promising phase 2 data for AlphaMedix in gastroenteropancreatic neuroendocrine tumors; and expedited FDA review for Tzield to delay progression of stage 3 type 1 diabetes. These updates reflect Sanofi’s ongoing commitment to advancing treatments for various medical conditions.